… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology … Biology/Molecular Biology. What is Klein’s connection to RNA therapeutics? “At the end of the 80s, I wrote my master’s …
… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
… Always excited about RNA therapies He is one of the founders of ProQR, but even … as they say. Gerard Platenburg What made you pursue RNAtherapy as a potential treatment for these diseases? “Well, …
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… study which aimed to explore whether the investigational RNAtherapy sepofarsen was effective and safe for individuals … more from the ongoing analyses and as they work to advance RNA therapies to potentially help children, adults, and …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … (SAB) with leaders in inherited retinal disease and RNAtherapy. The SAB members are: James Shannon, MD, Chair of the …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … (SAB) with leaders in inherited retinal disease and RNAtherapy. In February, ProQR announced its participation in …
